Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from LSL Pharma Group Inc ( (TSE:LSL) ).
LSL Pharma Group’s Juno OTC unit has signed a binding term sheet with Instapill Private Limited to supply private label Loratadine 10 mg rapid dissolve tablets to Canadian retailers, targeting launch in June 2027 subject to Health Canada approval. The product, which is bioequivalent to Claritin RDT, strengthens LSL Pharma’s position in the $60 million Canadian over-the-counter allergy market, which is growing at about 8% annually.
The deal extends Juno OTC’s successful partnership with Instapill, already proven through the widely distributed Loperamide 2 mg RDT, and secures a broader pipeline of rapid dissolve formulations aimed at convenience and better patient compliance. With more than 40 OTC products on the market and 10 more expected within a year, LSL Pharma is positioning Juno OTC as a leading private label supplier in high-volume categories, supporting sustained revenue growth and bolstering its profile in consumer health.
More about LSL Pharma Group Inc
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of sterile ophthalmic medicines, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid forms. Through subsidiaries including Juno OTC Inc., it serves the Canadian private label consumer healthcare market, supplying major retailers with over-the-counter products under their own brands and leveraging strong regulatory and quality assurance expertise.
Average Trading Volume: 73,836
Technical Sentiment Signal: Sell
Current Market Cap: C$46.89M
See more insights into LSL stock on TipRanks’ Stock Analysis page.